These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 8743335)

  • 1. Clinical pharmacokinetics of metformin.
    Scheen AJ
    Clin Pharmacokinet; 1996 May; 30(5):359-71. PubMed ID: 8743335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of metformin.
    Graham GG; Punt J; Arora M; Day RO; Doogue MP; Duong JK; Furlong TJ; Greenfield JR; Greenup LC; Kirkpatrick CM; Ray JE; Timmins P; Williams KM
    Clin Pharmacokinet; 2011 Feb; 50(2):81-98. PubMed ID: 21241070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency.
    Harrower AD
    Clin Pharmacokinet; 1996 Aug; 31(2):111-9. PubMed ID: 8853933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring metformin in cardiac patients exposed to contrast media using ultra-high-performance liquid chromatography tandem mass-spectrometry.
    Radwan MA; Al Taweel ES; Al-Moghairi AM; Aloudah NM; Al Babtain MA; Al-Amri HS
    Ther Drug Monit; 2011 Dec; 33(6):742-9. PubMed ID: 22105592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihyperglycaemic agents. Drug interactions of clinical importance.
    Scheen AJ; Lefèbvre PJ
    Drug Saf; 1995 Jan; 12(1):32-45. PubMed ID: 7741982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.
    Dunn CJ; Peters DH
    Drugs; 1995 May; 49(5):721-49. PubMed ID: 7601013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
    Scheen AJ
    Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Traditional contraindications to the use of metformin -- more harmful than beneficial?].
    Holstein A; Egberts EH
    Dtsch Med Wochenschr; 2006 Jan; 131(3):105-10. PubMed ID: 16418951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin and contrast media: where is the conflict?
    Rasuli P; Hammond DI
    Can Assoc Radiol J; 1998 Jun; 49(3):161-6. PubMed ID: 9640281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic optimisation of oral hypoglycaemic therapy.
    Marchetti P; Giannarelli R; di Carlo A; Navalesi R
    Clin Pharmacokinet; 1991 Oct; 21(4):308-17. PubMed ID: 1760902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin and other antidiabetic agents in renal failure patients.
    Lalau JD; Arnouts P; Sharif A; De Broe ME
    Kidney Int; 2015 Feb; 87(2):308-22. PubMed ID: 24599253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of the antihyperglycemic agent metformin in cats.
    Michels GM; Boudinot FD; Ferguson DC; Hoenig M
    Am J Vet Res; 1999 Jun; 60(6):738-42. PubMed ID: 10376904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function.
    Duong JK; Kumar SS; Kirkpatrick CM; Greenup LC; Arora M; Lee TC; Timmins P; Graham GG; Furlong TJ; Greenfield JR; Williams KM; Day RO
    Clin Pharmacokinet; 2013 May; 52(5):373-84. PubMed ID: 23475568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of metformin (N,N-dimethylbiguanide) in man.
    Sirtori CR; Franceschini G; Galli-Kienle M; Cighetti G; Galli G; Bondioli A; Conti F
    Clin Pharmacol Ther; 1978 Dec; 24(6):683-93. PubMed ID: 710026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone.
    Geary RS; Bradley JD; Watanabe T; Kwon Y; Wedel M; van Lier JJ; VanVliet AA
    Clin Pharmacokinet; 2006; 45(8):789-801. PubMed ID: 16884318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus.
    Hong Y; Rohatagi S; Habtemariam B; Walker JR; Schwartz SL; Mager DE
    J Clin Pharmacol; 2008 Jun; 48(6):696-707. PubMed ID: 18372428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using a semi-mechanistic model to identify the main sources of variability of metformin pharmacokinetics.
    Stage TB; Wellhagen G; Christensen MMH; Guiastrennec B; Brøsen K; Kjellsson MC
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):105-114. PubMed ID: 30267605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
    Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function.
    Duong JK; Kroonen MYAM; Kumar SS; Heerspink HL; Kirkpatrick CM; Graham GG; Williams KM; Day RO
    Eur J Clin Pharmacol; 2017 Aug; 73(8):981-990. PubMed ID: 28451709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.